E-LIB Suche - Ergebnisse für: Hardt, Karin

1

Mechanistic modeling projections of antibody persistence af..:

Dari, Anna ; Jacqmin, Philippe ; Iwaki, Yuki...
CPT: Pharmacometrics & Systems Pharmacology. 12 (2023) 10 - p. 1485-1498 , 2023

Link: https://doi.org/10.1002/..

2

Thrombosis with thrombocytopenia syndrome: A database revie..:

Struyf, Frank ; Hardt, Karin ; Van Rampelbergh, Rian...
Vaccine. 41 (2023) 37 - p. 5351-5359 , 2023

Link: https://doi.org/10.1016/..

3

Efficacy, safety, and immunogenicity of a booster regimen o..:

Hardt, Karin ; Vandebosch, An ; Sadoff, Jerald...
The Lancet Infectious Diseases. 22 (2022) 12 - p. 1703-1715 , 2022

Link: https://doi.org/10.1016/..

4

A Plain Language Summary of the Janssen COVID-19 Vaccine Ef..:

Struyf, Frank ; Sadoff, Jerald ; Hardt, Karin.
Future Virology. 17 (2022) 11 - p. 777-799 , 2022

Link: https://doi.org/10.2217/..

5

Distinctive mutational spectrum and karyotype disruption in..:

Skowron, Margaretha A. ; Petzsch, Patrick ; Hardt, Karin...
Scientific Reports. 9 (2019) 1 - p. , 2019

Link: https://doi.org/10.1038/..

6

Vaccine strategies: Optimising outcomes:

Hardt, Karin ; Bonanni, Paolo ; King, Susan...
Vaccine. 34 (2016) 52 - p. 6691-6699 , 2016

Link: https://doi.org/10.1016/..

7

Primary and booster vaccination with an inactivated poliovi..:

Li, Rongcheng ; Li, Chang Gui ; Li, Yanping...
Vaccine. 34 (2016) 12 - p. 1436-1443 , 2016

Link: https://doi.org/10.1016/..

8

Lasting immune memory against hepatitis B following challen..:

Avdicova, Mária ; Crasta, Priya D. ; Hardt, Karin.
Vaccine. 33 (2015) 23 - p. 2727-2733 , 2015

Link: https://doi.org/10.1016/..

9

Immunogenicity and reactogenicity of a decennial booster do..:

Kovac, Martina ; Rathi, Niraj ; Kuriyakose, Sherine..
Vaccine. 33 (2015) 22 - p. 2594-2601 , 2015

Link: https://doi.org/10.1016/..

10

656Immunogenicity and Safety Evaluation of a New Syringe Pr..:

De La O, Manuel ; Abarca, Katia ; Lepetic, Alejandro...
Open Forum Infectious Diseases. 1 (2014) suppl_1 - p. S184-S184 , 2014

Link: https://doi.org/10.1093/..

11

Model based estimates of long-term persistence of inactivat..:

Hens, Niel ; Habteab Ghebretinsae, Aklilu ; Hardt, Karin..
Vaccine. 32 (2014) 13 - p. 1507-1513 , 2014

Link: https://doi.org/10.1016/..

12

Sustaining Vaccine Confidence in the 21st Century:

Hardt, Karin ; Schmidt-Ott, Ruprecht ; Glismann, Steffen..
Vaccines. 1 (2013) 3 - p. 204-224 , 2013

Link: https://doi.org/10.3390/..

13

One virus, one lesion—individual components of CIN lesions ..:

Quint, Wim ; Jenkins, David ; Molijn, Anco...
The Journal of Pathology. 227 (2012) 1 - p. 62-71 , 2012

Link: https://doi.org/10.1002/..

14

Immunogenicity of Infanrix™ hexa administered at 3, 5 and 1..:

Van Der Meeren, Olivier ; Kuriyakose, Sherine ; Kolhe, Devayani.
Vaccine. 30 (2012) 17 - p. 2710-2714 , 2012

Link: https://doi.org/10.1016/..

15

Immunogenicity of the reduced-antigen-content dTpa vaccine ..:

Van Damme, Pierre ; McIntyre, Peter ; Grimprel, Emmanuel...
Vaccine. 29 (2011) 35 - p. 5932-5939 , 2011

Link: https://doi.org/10.1016/..